Research in liver cancer
We are always learning more about cancer. Researchers and healthcare professionals use what they learn from research studies to develop better ways to treat liver cancer. The following is a selection of research showing promise for treating liver cancer.
We’ve included information from the following sources. Each item has an identity number that links to a brief overview (abstract).
- PubMed, US National Library of Medicine (PMID)
- American Society of Clinical Oncology (ASCO)
- Canadian Cancer Trials and ClinicalTrials.gov (NCT)
Researchers are looking for the best ways to treat liver cancer using surgery and improve how surgery is done.
A laparoscopic liver resection is when the surgeon makes small cuts (incisions) in the abdomen and then inserts an
Ablation therapy @(Model.HeadingTag)>
The most common ablation therapy used for liver cancer is radiofrequency
Microwave ablation uses heat made from microwaves to destroy cancer cells (called hyperthermia treatment). The heat is delivered by a needle placed through the skin and into a tumour. Research shows that microwave ablation may help improve survival in people with hepatocellular carcinoma (ClinicalTrials.gov, NCT 02859753; Clinical Radiology, PMID 27890422).
Irreversible electroporation (IRE) uses a needle that delivers electrical energy directly to the tumour. It has the advantage of killing cancer cells without creating extreme heat or cold. Studies show that IRE seems to be a safe treatment for small liver tumours and that it controls the growth of tumours (European Journal of Surgical Oncology, PMID 28109674).
Targeted therapy @(Model.HeadingTag)>
The standard targeted therapy drug used for advanced liver cancer is sorafenib (Nexavar). Researchers are studying other targeted therapy drugs to treat liver cancer.
Ramucirumab (Cyramza) was studied in the REACH trial, which looked at how it worked in people with advanced liver cancer after they had sorafenib. Ramucirumab improved survival in people who had a higher alpha-fetoprotein (AFP) level than normal (European Journal of Cancer, PMID 28591675;ASCO, Abstract TPS538; Canadian Cancer Trials, NCT 02435433).
Regorafenib (Stivarga) may be a treatment option for people with hepatocellular carcinoma if sorafenib stops working and the cancer continues to grow and spread (progresses). An international phase 3 clinical trial showed regorafenib helps prolong survival. More research is needed to see if regorafenib can be combined with other treatments (Lancet, PMID 27932229).
Cabozantinib (Cabometyx) is a
Apatinib is also a tyrosine kinase inhibitor. Research shows that people treated with apatinib had longer
Radiation therapy @(Model.HeadingTag)>
The following is noteworthy research into radiation therapy for liver cancer.
Radioembolization (also called selective internal radiation therapy) gives radiation directly to tumours using tiny radioactive beads (called microspheres). Using a
Stereotactic body radiation therapy (SBRT) delivers precisely targeted high doses of radiation to tumours in fewer sessions (fractions). It creates many beams of radiation from different angles that meet at the tumour. The tumour receives a high dose of radiation, while the surrounding tissue gets less radiation from the individual beams. This lowers the effects of radiation on healthy tissue near the tumour. A phase 3 clinical trial is studying how well SBRT and sorafenib work to treat liver cancer compared to sorafenib alone. Combining these 2 treatments may kill more cancer cells (Canadian Cancer Trials, NCT 01730937).
Combining treatments @(Model.HeadingTag)>
Researchers are combining transarterial chemoembolization (TACE), radiofrequency ablation (RFA) and sorafenib with other treatments to see if they improve treatment response and survival in people with liver cancer.
Sorafenib combined with DEB-TACE has been studied in clinical trials for people with liver cancer. DEB stands for drug-eluting beads, which are injected into the hepatic artery. Results of one trial show that this treatment combination improved survival in people with advanced liver cancer (Radiology, PMID 26069923). But other trials have not shown the same benefit of this combination (The Lancet Gastroenterology & Hepatology, PMID 28648803; Journal of Hepatology, PMID 26809111).
TACE with RFA has been studied as a treatment for early hepatocellular carcinoma instead of having liver resection surgery. A review of many studies (called a systematic review) shows that surgery has better survival and a lower chance of the cancer coming back (recurrence rate) than TACE plus RFA (The American Surgeon, PMID 29580359). But research also shows that TACE plus RFA improves survival compared to using TACE alone (Oncotarget, PMID 27936465).
Arsenic trioxide (Trisenox) given after TACE was compared to using TACE alone in a group of people with liver cancer that had spread to the lung (pulmonary metastasis). The study results suggest that giving arsenic trioxide after TACE was a more effective treatment than TACE alone. Liver tumours responded better to arsenic trioxide after TACE and there were fewer cases where the cancer spread outside the liver with this treatment (Journal of Gastroenterology and Hepatology, PMID 27517972).
Radioembolization (using TheraSphere yttrium-90 glass microspheres) combined with sorafenib is being studied to see if it is a better treatment than sorafenib alone for liver cancer that can’t be removed by surgery. Results are not yet published (JMIR Research Protocols, PMID 30111528).
Learn more about cancer research @(Model.HeadingTag)>
Researchers continue to try to find out more about liver cancer. Clinical trials are research studies that test new ways to treat liver cancer. They also look at ways to prevent, find and manage liver cancer.
Clinical trials provide information about the safety and effectiveness of new approaches to see if they should become widely available. Most of the standard treatments for liver cancer were first shown to be effective through clinical trials.
Find out more about clinical trials.
American College of Radiology (ACR) and the Radiological Society of North America (RSNA) . Radioembolization . Oak Brook : Radiological Society of North America, Inc ; 2013 .
Pancreatic Cancer Action. Irreversible Electroporation (NanoKnife®). Hampshire, UK: 2017: https://pancreaticcanceraction.org/about-pancreatic-cancer/treatment/radiotherapy/irreversible-electroporation-nanoknife/.
Radiological Society of North America. Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT). 2017.
Radiological Society of North America. Radiofrequency Ablation (RFA) / Microwave Ablation (MWA) of Liver Tumors. 2017: https://www.radiologyinfo.org/en/info.cfm?pg=rfaLiver.